Cancer tissue of origin constrains the growth and metabolism of metastases.

Journal

Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592

Informations de publication

Date de publication:
19 Aug 2024
Historique:
received: 31 05 2024
accepted: 09 07 2024
medline: 20 8 2024
pubmed: 20 8 2024
entrez: 19 8 2024
Statut: aheadofprint

Résumé

Metastases arise from subsets of cancer cells that disseminate from the primary tumour

Identifiants

DOI: 10.1038/s42255-024-01105-9 PMID: 39160333
pubmed: 39160333
doi: 10.1038/s42255-024-01105-9
pii: 10.1038/s42255-024-01105-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R35CA242379
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : P30CA14051
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01CA201276

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Yang, D. et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 185, 1905–1923 (2022).
pubmed: 35523183 pmcid: 9452598 doi: 10.1016/j.cell.2022.04.015
Celià-Terrassa, T. & Kang, Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 30, 892–908 (2016).
pubmed: 27083997 pmcid: 4840296 doi: 10.1101/gad.277681.116
Boutin, A. T. et al. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 31, 370–382 (2017).
pubmed: 28289141 pmcid: 5358757 doi: 10.1101/gad.293449.116
Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49, 358–366 (2017).
pubmed: 28092682 pmcid: 5663439 doi: 10.1038/ng.3764
Muir, A. & Vander Heiden, M. G. The nutrient environment affects therapy. Science 360, 962–963 (2018).
pubmed: 29853672 pmcid: 6368963 doi: 10.1126/science.aar5986
Abbott, K. L. et al. Screening in serum-derived medium reveals differential response to compounds targeting metabolism. Cell Chem. Biol. 30, 1156–1168 (2023).
pubmed: 37689063 doi: 10.1016/j.chembiol.2023.08.007
Altea‐Manzano, P., Cuadros, A. M., Broadfield, L. A. & Fendt, S. Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take. EMBO Rep. 21, e50635 (2020).
pubmed: 32964587 pmcid: 7534637 doi: 10.15252/embr.202050635
Mayers, J. R. et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353, 1161–1165 (2016).
pubmed: 27609895 pmcid: 5245791 doi: 10.1126/science.aaf5171
Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157–170 (2012).
pubmed: 22326218 pmcid: 3282107 doi: 10.1016/j.cmet.2011.12.015
Sullivan, M. R. et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife 8, e44235 (2019).
pubmed: 30990168 pmcid: 6510537 doi: 10.7554/eLife.44235
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
pubmed: 33828302 pmcid: 8122068 doi: 10.1038/s41586-021-03442-1
Ferraro, G. B. et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat. Cancer 2, 414–428 (2021).
pubmed: 34179825 pmcid: 8223728 doi: 10.1038/s43018-021-00183-y
Schild, T., Low, V., Blenis, J. & Gomes, A. P. Unique metabolic adaptations dictate distal organ-specific metastatic colonization. Cancer Cell 33, 347–354 (2018).
pubmed: 29533780 pmcid: 5889305 doi: 10.1016/j.ccell.2018.02.001
Lehúede, C., Dupuy, F., Rabinovitch, R., Jones, R. G. & Siegel, P. M. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res. 76, 5201–5208 (2016).
pubmed: 27587539 doi: 10.1158/0008-5472.CAN-16-0266
Bartman, C. R. et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature 614, 349–357 (2023).
pubmed: 36725930 pmcid: 10288502 doi: 10.1038/s41586-022-05661-6
Basnet, H. et al. Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. Elife 8, e43627 (2019).
pubmed: 30912515 pmcid: 6440742 doi: 10.7554/eLife.43627
Piskounova, E. et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191 (2015).
pubmed: 26466563 pmcid: 4644103 doi: 10.1038/nature15726
Gaude, E. & Frezza, C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat. Commun. 7, 13041 (2016).
pubmed: 27721378 pmcid: 5062467 doi: 10.1038/ncomms13041
Hu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522–529 (2013).
pubmed: 23604282 pmcid: 3681899 doi: 10.1038/nbt.2530
Fidler, I. J. The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3, 453–458 (2003).
pubmed: 12778135 doi: 10.1038/nrc1098
Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).
pubmed: 15894267 doi: 10.1016/j.ccr.2005.04.023
Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315–1326 (2009).
pubmed: 20064377 pmcid: 2810531 doi: 10.1016/j.cell.2009.11.025
Gejman, R. S. et al. Rejection of immunogenic tumor clones is limited by clonal fraction. Elife 7, e41090 (2018).
pubmed: 30499773 pmcid: 6269121 doi: 10.7554/eLife.41090
Obenauf, A. C. & Massagué, J. Surviving at a distance: organ-specific metastasis. Trends Cancer 1, 76–91 (2015).
pubmed: 28741564 pmcid: 4673677 doi: 10.1016/j.trecan.2015.07.009
Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086–1097 (2015).
pubmed: 26209539 pmcid: 4657730 doi: 10.1158/2159-8290.CD-15-0120
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).
pubmed: 28187288 pmcid: 5308465 doi: 10.1016/j.cell.2016.11.037
Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150–1162 (2021).
pubmed: 34115987 pmcid: 8782207 doi: 10.1016/j.ccell.2021.05.005
Elia, I., Doglioni, G. & Fendt, S. M. Metabolic hallmarks of metastasis formation. Trends Cell Biol. 28, 673–684 (2018).
pubmed: 29747903 doi: 10.1016/j.tcb.2018.04.002
Lau, A. N. et al. Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. Elife 9, e56782 (2020).
pubmed: 32648540 pmcid: 7406355 doi: 10.7554/eLife.56782
Ariston Gabriel, A. N. et al. Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance. Pancreatology 20, 79–88 (2020).
pubmed: 31780287 doi: 10.1016/j.pan.2019.11.006
Pérez-Mancera, P. A., Guerra, C., Barbacid, M. & Tuveson, D. A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079–1092 (2012).
pubmed: 22406637 doi: 10.1053/j.gastro.2012.03.002
Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science 368, eaaw5473 (2020).
pubmed: 32273439 pmcid: 7227780 doi: 10.1126/science.aaw5473
Yamaguchi, N. et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. Elife 8, e52135 (2019).
pubmed: 31841108 pmcid: 7299340 doi: 10.7554/eLife.52135
Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518–524 (2005).
pubmed: 16049480 pmcid: 1283098 doi: 10.1038/nature03799
Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005–1009 (2009).
pubmed: 19421193 pmcid: 2698953 doi: 10.1038/nature08021
DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072 (2009).
pubmed: 19561589 pmcid: 2757265 doi: 10.1038/nprot.2009.95
Kapanadze, T. et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 59, 1007–1013 (2013).
pubmed: 23796475 pmcid: 3805787 doi: 10.1016/j.jhep.2013.06.010
Zender, L. et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb. Symp. Quant. Biol. 70, 251–261 (2005).
pubmed: 16869761 pmcid: 4595853 doi: 10.1101/sqb.2005.70.059
Raphael, B. J. et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203 (2017).
doi: 10.1016/j.ccell.2017.07.007
Aguirre, A. J. et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 8, 1096–1111 (2018).
pubmed: 29903880 pmcid: 6192263 doi: 10.1158/2159-8290.CD-18-0275
Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27, 57–71 (2015).
pubmed: 25584894 pmcid: 4297291 doi: 10.1016/j.ccell.2014.12.002
Elia, I. et al. Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature 568, 117–121 (2019).
pubmed: 30814728 pmcid: 6451642 doi: 10.1038/s41586-019-0977-x
Rinaldi, G. et al. In Vivo evidence for serine biosynthesis-defined sensitivity of lung metastasis, but not of primary breast tumors, to mTORC1 inhibition. Mol. Cell 81, 386–397 (2021).
pubmed: 33340488 doi: 10.1016/j.molcel.2020.11.027
Elia, I. et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat. Commun. 8, 15267 (2017).
pubmed: 28492237 pmcid: 5437289 doi: 10.1038/ncomms15267
Chi, Y. et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science 369, 276–282 (2020).
pubmed: 32675368 pmcid: 7816199 doi: 10.1126/science.aaz2193
Klein, C. A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302–312 (2009).
pubmed: 19308069 doi: 10.1038/nrc2627
Oda, T. et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int. J. Urol. 8, 473–477 (2001).
pubmed: 11683965 doi: 10.1046/j.1442-2042.2001.00353.x
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
pubmed: 25557080 doi: 10.1016/j.cell.2014.12.021
Gocheva, V. et al. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc. Natl Acad. Sci. USA 114, E5625–E5634 (2017).
pubmed: 28652369 pmcid: 5514763 doi: 10.1073/pnas.1707054114
Davidson, S. M. et al. Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab. 23, 517–528 (2016).
pubmed: 26853747 pmcid: 4785096 doi: 10.1016/j.cmet.2016.01.007

Auteurs

Sharanya Sivanand (S)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Yetis Gultekin (Y)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Peter S Winter (PS)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.

Sidney Y Vermeulen (SY)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Konstantine M Tchourine (KM)

Department of Systems Biology, Columbia University Medical Center, New York, NY, USA.
ORCID: 0000-0002-0647-5272

Keene L Abbott (KL)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
ORCID: 0000-0002-6166-704X

Laura V Danai (LV)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biochemistry and Molecular Biology, University of Massachusetts Amherst, Amherst, MA, USA.

Florian Gourgue (F)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0001-9777-806X

Brian T Do (BT)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0003-4992-2623

Kayla Crowder (K)

Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

Tenzin Kunchok (T)

Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
ORCID: 0000-0001-6603-4607

Allison N Lau (AN)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0003-4250-7355

Alicia M Darnell (AM)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Alexandria Jefferson (A)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

Satoru Morita (S)

Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Dan G Duda (DG)

Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-7065-8797

Andrew J Aguirre (AJ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-0701-6203

Brian M Wolpin (BM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
ORCID: 0000-0002-0455-1032

Nicole Henning (N)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Preclinical Imaging and Testing Facility, Massachusetts Institute of Technology, Cambridge, MA, USA.

Virginia Spanoudaki (V)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Preclinical Imaging and Testing Facility, Massachusetts Institute of Technology, Cambridge, MA, USA.

Laura Maiorino (L)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0001-8217-1337

Darrell J Irvine (DJ)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Ragon Institute of MGH, MITnd Harvard, Cambridge, MA, USA.
ORCID: 0000-0002-8637-1405

Omer H Yilmaz (OH)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Pathology, Massachusetts General Hospital and Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-7577-4612

Caroline A Lewis (CA)

Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
ORCID: 0000-0003-1787-5084

Dennis Vitkup (D)

Department of Systems Biology, Columbia University Medical Center, New York, NY, USA.
Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA.

Alex K Shalek (AK)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ragon Institute of MGH, MITnd Harvard, Cambridge, MA, USA.
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0001-5670-8778

Matthew G Vander Heiden (MG)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. mvh@mit.edu.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. mvh@mit.edu.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. mvh@mit.edu.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. mvh@mit.edu.
ORCID: 0000-0002-6702-4192

Classifications MeSH